The UMCG website shows YouTube videos. YouTube places cookies if you watch them. Choose ‘Rather not’ if you do not want these cookies. We also place cookies of our own. These help us improve the usability of our website.
More on our cookie policy.
Diabetes is increasing rapidly from 415 million patients in 2015 to 642 million patients by 2040. As a result, it will become the leading disease worldwide, affecting 1 out of 10 persons globally and 3 out of 4 in low and middle income countries.
The World Health Organisation marked World Health Day 2016 as calling for action on diabetes. Despite successful treatment of the inadequate glucose handling, diabetic patients show long-term effects of the disease such as a progressive loss of multiple organ function, in particular in the cardiovascular and renal systems. About half of the diabetic patients are at risk for renal complications associated with a markedly increased disease burden and death rate, the latter even surpassing the death rate in all treated cancer patients. We train and educates in 4 main pillars. We will contribute to the implementation and optimalisatoin of personalised medicine in all of these societal domains.
The major reason for the lack of treatment efficacy is the large variation in individual response to the treatment. Consequently, we are left with a huge unmet need in the treatment of this chronic disease. A huge step forward in chronic diabetes disease management is personalised medicine. The EC has recognised the importance of personalised medicine and has started initiatives in this regard in 2016. The COFUND PROMINENT programme of the Research Institute for Drug Exploration (GUIDE) brings these fields together and introduces personalised medicine for chronic diabetes disease management.
Introduction to PROMINENT
Watch video
Scan QR-code
Discover our research
More news
Relevance
How our research benefits to society
We are focussed at setting up a dedicated doctoral training programme for Early Stage Researchers (ESRs) at the University Medical Center Groningen (UMCG) and the University of Groningen (RUG). We aim to select the best students to become excellently trained researchers, who can perform high quality research, and who subsequently have a major impact on scientific breakthroughs that foster the European society and economy in this field.
-
Disease Mechanisms
- Project 1.1. Genomics guided drug repositioning in asthma
- Project 1.2. The bile acid receptor as treatment in liver disease
- Project 1.3. Epigenetic regulation of the inflammatory response in type 2 diabetes
- Project 1.4. Immune signatures in chronic inflammatory diseases: focus on interleuking-6
- Project 1.5. Microfluidic endothelial disease models for precision medicine
- Project 1.6. Exocrine-endocrine interactions
Drug Development
- Project 2.1 Targeting protein-protein interaction of macrophage micration inhibitory factor (MIF) in diabetes
- Project 2.2 Development of antibacterial drugs for diabetic infections
- Project 2.3 In-vitro disease modeling in diabetic cardiomyopathy
Drug Registration and Evaluation
- Project 3.1 Personalised diabetes treatment decisions in primary care
- Project 3.2. Incorporating patient preferences in regulatory decisions for antidiabetic drugs
- Project 3.3 Cost-effectiveness of personalised diabetes treatment
Drug Application
- Project 4.1 Integrating multiple effects of single drugs to tailor type 2 diabetes
- Project 4.2 Biomarker signatures for disease and drug response prediction
- Project 4.3 Analysis of Lifestyle Patterns for Improvement of Diabetes
- Project 4.4 Is atrial fibrillation a mechanism or a bystander in heart failure?
-
read more about our Training Schools
-
The prominent training program (project number 754425) has received funding from the Marie Skłodowska-Curie COFUND instrument as part of the European Horizon 2020 programme. Through this instrument, the European Commission aims to develop the research skills of young researchers and offer them better career perspectives.
Prominent is a project of the Research Institute GUIDE and CoFunded by:
- European Union's Horizon2020 COFUND
- University of Groningen (RUG)
- University Medical Center Groningen (UMCG)
- Faculty of Science and Engineering
- Research Institute GUIDE
- Research Institute GRIP
-
- University Medical Center of Hamburg-Eppendorf (DE)
- TNO (NL)
- Biomarker Development Center (NL)
- National Institute for Public Health and the Environment (RIVM)
- Institut National de la santé et de la recherche médicale (INSERM) F
- University of Pittsburgh (US)
- SYNCOM (NL)
- University of Uppsala (SE)
- The George Institute for Global Health Australia (AUS)
- PRA Health Sciences (NL)
- University of Michigan (US)
- University of Exeter (UK)
- Steno Diabetes Center (DK)
- GIANTT (NL)
- University of Mannheim-Heidelberg (DE)
- McMaster University (CA)
- University of Birmingham (UK)
- University of Kansas (US)
- TelesisPharma (NL)
- Univeristy of milan (I)
- De Friesland ZorgVerzekeraar (NL)
- Massachusetts General Hospital: Broad Institute of MIT and Harvard University (US)
- Karolinska Institute (SE)
- TransplantLines (NL)
- PREVEND (NL)
- Lund University (SE)
- G-CURE (NL)
- Health Innovation Technology Transfer (ES)
- CBG-MEB (NL)
- Certe (NL)
- Aquilo BV (NL)
- University of Florida (US)
- National Heart Centre Singapore (MY)
-
Interested in the latest updates of the PROMINENT project?
Sign up for the newsletter Prominent project by sending an e-mail indicating your interest, your name, e-mail address and relationship (e.g. Partner, Researcher, Citizin).
Your details will only be used for sending this newsletter. If you do not want to receive the newsletter anymore, you can sign out at any time by sending an e-mail to the same address. Your details will then be deleted from the list of receivers.
Contact
Program manager / Group leader
Sieta de Vries
Executive coordinator research
Hiddo Heerspink
Executive coordinator training
Sven van IJzendoorn
University Medical Center Groningen (UMCG)
Institue GUIDE - PROMINENT
P.O. Box 196
9700 AD Groningen
The Netherlands
University Medical Center Groningen (UMCG)
Institue GUIDE - PROMINENT
Ant. Deusinglaan 1
9713 AV Groningen
The Netherlands